137 related articles for article (PubMed ID: 8713613)
21. Retention of antimony in hair during leishmaniasis treatment.
Dorea JG; Merchan-Hamann E; Ryan DE; Holzbecher J
Clin Chim Acta; 1989 Feb; 179(3):341-5. PubMed ID: 2714007
[No Abstract] [Full Text] [Related]
22. Atypical mucocutaneous involvement with Leishmania donovani.
Pulimood SA; Rupali P; Ajjampur SS; Thomas M; Mehrotra S; Sundar S
Natl Med J India; 2012; 25(3):148-50. PubMed ID: 22963292
[TBL] [Abstract][Full Text] [Related]
23. Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis.
Goyonlo VM; Vahabi-Amlashi S; Taghavi F
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():177-179. PubMed ID: 31492621
[TBL] [Abstract][Full Text] [Related]
24. Mucosal leishmaniasis and miltefosine.
Tuon FF; Amato VS
Clin Infect Dis; 2007 Jun; 44(11):1525-6; author reply 1526-7. PubMed ID: 17479959
[No Abstract] [Full Text] [Related]
25. Mucocutaneous leishmaniasis: report of a case with massive involvement of nasal, pharyngeal and laryngeal mucosa.
Di Lella F; Vincenti V; Zennaro D; Afeltra A; Baldi A; Giordano D; Pasanisi E; Bacciu A; Bacciu S; Di Lella G
Int J Oral Maxillofac Surg; 2006 Sep; 35(9):870-2. PubMed ID: 16574379
[No Abstract] [Full Text] [Related]
26. Topical 15% Paromomycin-Aquaphilic for Bolivian Leishmania braziliensis Cutaneous Leishmaniasis: A Randomized, Placebo-controlled Trial.
Soto J; Soto P; Ajata A; Luque C; Tintaya C; Paz D; Rivero D; Berman J
Clin Infect Dis; 2019 Feb; 68(5):844-849. PubMed ID: 30260376
[TBL] [Abstract][Full Text] [Related]
27. Intralesional glucantime in Leishmania braziliensis braziliensis infections.
Barrios LA; Costa JM; Netto EM; Vexenat CO; Cuba CC; Marsden PD
Trans R Soc Trop Med Hyg; 1986; 80(1):173-4. PubMed ID: 3726989
[No Abstract] [Full Text] [Related]
28. A case of multiple lesion mucocutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis infection.
Goto H; Sotto MN; Corbett CE; Villaça Neto CM; Laczynski CM; Shaw JJ
J Trop Med Hyg; 1990 Feb; 93(1):48-51. PubMed ID: 2304132
[TBL] [Abstract][Full Text] [Related]
29. Case Report: Mucosal Leishmaniasis in New York City.
Murray HW; Eiras DP; Kirkman LA; Chai RL; Caplivski D
Am J Trop Med Hyg; 2020 Jun; 102(6):1319-1322. PubMed ID: 32228792
[TBL] [Abstract][Full Text] [Related]
30. [A patient with long-term, unrecognized leishmaniasis].
Rabelink NM; de Steenwinkel JE; van Biezen P; van Daele PL; Gyssens IC
Ned Tijdschr Geneeskd; 2006 Dec; 150(49):2715-9. PubMed ID: 17194010
[TBL] [Abstract][Full Text] [Related]
31. Case Report: Unusual Presentation of Pharyngeal Mucosal Leishmaniasis due to
Figueiredo LP; Almeida LDC; Magalhães A; Arruda S; Lessa MM; Carvalho EM
Am J Trop Med Hyg; 2020 Oct; 103(4):1493-1495. PubMed ID: 32748768
[TBL] [Abstract][Full Text] [Related]
32. Reactivation of mucosal and cutaneous leishmaniasis in a renal transplanted patient.
Tuon FF; Bombonatto GM; Battaglin ER; Sakumoto MH; Amato VS; de Camargo RA; Nicodemo AC
Am J Trop Med Hyg; 2014 Jul; 91(1):81-3. PubMed ID: 24732458
[TBL] [Abstract][Full Text] [Related]
33. Tilting the balance between RNA interference and replication eradicates Leishmania RNA virus 1 and mitigates the inflammatory response.
Brettmann EA; Shaik JS; Zangger H; Lye LF; Kuhlmann FM; Akopyants NS; Oschwald DM; Owens KL; Hickerson SM; Ronet C; Fasel N; Beverley SM
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):11998-12005. PubMed ID: 27790981
[TBL] [Abstract][Full Text] [Related]
34. Mucosal relapse one year after complete remission of cutaneous sporotrichoid leishmaniasis due to Leishmania braziliensis.
Ntasou AA; Grummich H; Fischer K; Baur V; Bonkowsky V; Birkmann J; Schultz ES
Eur J Dermatol; 2016; 26(1):94-5. PubMed ID: 26462596
[No Abstract] [Full Text] [Related]
35. Mucosal leishmaniasis of the tongue caused by Leishmania infantum in an immunocompetent woman.
Pampín Franco A; Gamo Villegas R; Caro-Gutiérrez D; López-Estebaranz JL; Pinedo F
Int J Dermatol; 2015 Jan; 54(1):e39-41. PubMed ID: 25312835
[No Abstract] [Full Text] [Related]
36. Clinical complexity of Leishmania (Viannia) braziliensis infections amongst travelers.
Eichner S; Thoma-Uszynski S; Herrgott I; Sebald H; Debus A; Tsianakas A; Ehrchen J; Harms G; Simon M; Sunderkötter C; Bogdan C
Eur J Dermatol; 2013 Apr; 23(2):218-23. PubMed ID: 23557633
[TBL] [Abstract][Full Text] [Related]
37. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
[TBL] [Abstract][Full Text] [Related]
38. Clinical characteristics of human Leishmania braziliensis braziliensis infections.
Llanos Cuentas EA; Cuba CC; Barreto AC; Marsden PD
Trans R Soc Trop Med Hyg; 1984; 78(6):845-6. PubMed ID: 6533860
[No Abstract] [Full Text] [Related]
39. [Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis].
Correia D; Macêdo VO; Carvalho EM; Barral A; Magalhães AV; de Abreu MV; Orge ML; Marsden P
Rev Soc Bras Med Trop; 1996; 29(5):447-53. PubMed ID: 8966308
[TBL] [Abstract][Full Text] [Related]
40. Development of Leishmania (Viannia) panamensis lesions and relationship of numbers of amastigotes to lesion area on antimony-treated and untreated hamsters.
Hanson WL; Chapman WL; Waits VB; Lovelace JK
J Parasitol; 1991 Oct; 77(5):780-3. PubMed ID: 1919929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
